NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

Oct. 22 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-12	€0.6200	0.00%	4,683
26-10-09	€0.6200	-2.97%	41,418
26-10-08	€0.6390	-3.18%	39,296
26-10-07	€0.6600	+0.92%	27,577
26-10-06	€0.6540	+0.62%	51,854

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - NFL Biosciences

Company calendar

Market Closed - Euronext Paris 11:55:00 2026-10-12 am EDT			5-day change	1st Jan Change
0.6200 ^EUR	0.00%		-4.62%	-47.37%

Oct. 06	NFL Biosciences Provides Progress Update on NFL-101 and NFL-102 Clinical Programs in Smoking Cessation	CI
Jul. 28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI

Market Cap	7.86M 8.78M 7.32M 6.64M 12.53M 839M 12.61M 88.02M 34.46M 433M 32.97M 32.24M 1.39B	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	6.24M 6.97M 5.81M 5.27M 9.95M 666M 10.01M 69.88M 27.35M 344M 26.17M 25.59M 1.11B	EV / Sales 2024	370,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	ALNFL	Real-time
Deutsche Boerse AG	82F	Delayed
Börse Stuttgart	82F	Delayed

Oct. 06	NFL Biosciences Provides Progress Update on NFL-101 and NFL-102 Clinical Programs in Smoking Cessation	CI
Jul. 28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
Jul. 07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
Jun. 30	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
Jun. 30	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
Jun. 01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
Jun. 01	NFL Biosciences validates breakthrough in personalized medicine
May. 26	Glimmers of hope for Middle East peace grow brighter
May. 26	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
May. 25	NFL Biosciences files new patent application
May. 25	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
May. 11	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
May. 04	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI

NFL Biosciences Stock

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Valuation: NFL Biosciences

Chart: NFL Biosciences

Latest news: NFL Biosciences

Analysts' recommendations: NFL Biosciences

Press Releases: NFL Biosciences

News in other languages: NFL Biosciences

Quotes and Performance

Price Extremes

Managers and Directors: NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

25-10-20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
24-10-02	NFL Biosciences: Invest Securities reduces its target
24-07-15	NFL Biosciences: Invest Securities raises its target

Oct. 06	NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two Clinical Programs in Smoking Cessation	BU
Sep. 08	NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie	BU
Jul. 28	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation	BU
Jul. 07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
Jun. 30	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU

Oct. 06	NFL Biosciences : point d’étape en vue des prochains jalons créateurs de valeur pour ses deux programmes cliniques dans le sevrage tabagique
Sep. 08	NFL Biosciences présentera ses travaux sur le biomarqueur de NFL-101 à un Congrès
Sep. 08	NFL Biosciences présentera au 20ème Congrès de la Société Francophone de Tabacologie son approche de médecine personnalisée dans le sevrage tabagique
Jul. 28	NFL Biosciences dépose la demande d'autorisation de l'étude clinique de phase 2 TONIC évaluant NFL-102 dans le sevrage tabagique
Jul. 07	NFL Biosciences : Bilan semestriel du contrat de liquidité

1 week	-4.62%
Current month	-10.14%
1 month	-26.19%
3 months	-27.06%
6 months	-45.42%
Current year	-47.37%

1 week	0.61	0.68
1 month	0.61	0.85
Current year	0.61	1.85
1 year	0.61	1.85
3 years	0.61	3.28
5 years	0.55	4.29
10 years	0.55	5

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	2024-10-16
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	2023-02-26
Bruno Lafont CHM	Chairman	-	2024-10-16
Francis Ahner BRD	Director/Board Member	-	2021-05-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	0.00%	-4.62%	-49.68%	-59.10%	8.78M
WUXI APPTEC CO., LTD.	+0.03%	-5.67%	+50.74%	+76.76%	70.65B
ARGENX SE	+0.66%	-9.75%	+6.97%	+52.62%	51.22B
LONZA GROUP AG	+0.31%	-0.14%	+8.84%	+32.99%	48.04B
IQVIA HOLDINGS INC.	+0.90%	-1.46%	+32.32%	+32.69%	43.16B
REVOLUTION MEDICINES, INC.	+2.21%	-6.61%	+302.05%	+701.45%	41.57B
BEONE MEDICINES AG	-1.15%	-3.11%	+9.47%	+98.83%	39.84B
CELLTRION, INC.	+0.45%	-1.20%	+9.11%	+43.54%	30.87B
WUXI BIOLOGICS (CAYMAN) INC.	-3.42%	-13.04%	+39.63%	+2.55%	27.53B
BIONTECH SE	-1.16%	-1.84%	-6.09%	-11.99%	24.08B
Average	-0.21%	-3.54%	+40.34%	+97.03%	37.7B
Weighted average by Cap.	+0.00%	-3.47%	+52.84%	+120.27%

	2024	2025
Net sales	46 51.39 42.88 38.89 73.36 4.91K 73.82 515.33 201.73 2.53K 193.02 188.75 8.16K	188 210.01 175.26 158.96 299.82 20.08K 301.7 2.11K 824.47 10.36K 788.88 771.4 33.34K
Net income	-2.08M -2.32M -1.94M -1.76M -3.32M -222M -3.34M -23.31M -9.13M -115M -8.73M -8.54M -369M	-3.32M -3.71M -3.09M -2.81M -5.29M -354M -5.32M -37.17M -14.55M -183M -13.92M -13.61M -588M
Net Debt	-2.07M -2.32M -1.93M -1.75M -3.31M -221M -3.33M -23.22M -9.09M -114M -8.7M -8.5M -368M	-1.62M -1.81M -1.51M -1.37M -2.58M -173M -2.6M -18.14M -7.1M -89.24M -6.8M -6.64M -287M